UCB Completes the Acquisition of Ra Pharmaceuticals

UCB today announced that the acquisition of Ra Pharmaceuticals, Inc. has been successfully completed and Ra Pharma is now a wholly-owned subsidiary of UCB. The former Ra Pharma shareholders received US$ 48 in cash for each Ra Pharma share held at closing. Jean-Christophe Tellier, CEO UCB said: “In the last 15 months, we made several significant steps on UCB’s strategic growth path, namely the “Accelerate and Expand” phase. This acquisition is a key part of this progress and an excellent strategic fit with UCB’s strategy. Ra Pharma builds upon our collective strengths and talents and adds to our strong internal growth opportunities.”

Read the full article: UCB Completes the Acquisition of Ra Pharmaceuticals //

Source: https://www.prnewswire.com/news-releases/ucb-completes-the-acquisition-of-ra-pharmaceuticals–to-deliver-differentiated-therapies-to-patients-301034148.html

Scroll to Top